All In Biotech

Drug Trial Radar · NCT07221838

A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab

OCTAGON: A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients With Generalized Myasthenia Gravis Treated With Ravulizumab

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Mar 4, 2026

Primary completion

Aug 27, 2027

Study completion Aug 27, 2027

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 28, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, multicenter single arm study designed to evaluate the effectiveness and safety of a predefined oral corticosteroids (OCS) tapering schedule to reduce OCS use in adult participants with acetylcholine receptor positive (AChR+) generalized myasthenia gravis (gMG) being treated with intravenous ravulizumab.

Conditions

  • Generalized Myasthenia Gravis
  • gMG

Interventions

  • Oral Corticosteroid Tapering ScheduleProcedure

    During the tapering period, participant will follow an Oral Corticosteroid tapering schedule as applicable to the participant. The oral corticosteroid (prednisone/prednisolone) is provided as per standard medical care.

  • RavulizumabDrug

    Patients being treated with intravenous ravulizumab as part of their standard medical care.

  • Prednisone/PrednisoloneDrug

    Participants will continue with or be switched to prednisone/prednisolone as per standard medical care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Adult Participants With gMG Who Either: Discontinue Oral Corticosteroids (OCS) or Reduce Their Daily OCS Dosage ≤ 5 mg/day and Maintain this Status for ≥ 4 Weeks Without Clinical Deterioration of gMGTime frame: Up to approximately 32 weeks

Locations

12 sites in 4 countries. Site status is shown where the registry gives one.

  • Research Site

    Chicago, Illinois · Not yet recruiting

  • Research Site

    Schaumburg, Illinois · Not yet recruiting

  • Research Site

    Neptune City, New Jersey · Not yet recruiting

  • Research Site

    Raleigh, North Carolina · Recruiting

  • Research Site

    Knoxville, Tennessee · Not yet recruiting

  • Research Site

    Bochum, Germany · Not yet recruiting

  • Research Site

    Milan, Italy · Not yet recruiting

  • Research Site

    Naples, Italy · Not yet recruiting

  • Research Site

    Rome, Italy · Not yet recruiting

  • Research Site

    Ibaraki, Japan · Not yet recruiting

  • Research Site

    Kitakyushu-shi, Japan · Not yet recruiting

  • Research Site

    Kumamoto, Japan · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.